Pharmacokinetic characterization of favipiravir in patients with COVID-19.
| Autor: | Gülhan R; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Eryüksel E; Department of Pulmonary Medicine and Critical Care, Marmara University School of Medicine, Istanbul, Turkey., Gülçebi İdriz Oğlu M; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Çulpan Y; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Toplu A; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Kocakaya D; Department of Pulmonary Medicine and Critical Care, Marmara University School of Medicine, Istanbul, Turkey., Tigen E; Department of Infectious Disease and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey., Ertürk Şengel B; Department of Infectious Disease and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey., Sili U; Department of Infectious Disease and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey., Olgun Yıldızeli Ş; Department of Pulmonary Medicine and Critical Care, Marmara University School of Medicine, Istanbul, Turkey., Balcan MB; Department of Pulmonary Medicine and Critical Care, Marmara University School of Medicine, Istanbul, Turkey., Elçi A; Istanbul Health Directorate Public Health Laboratory-3, Istanbul, Turkey., Bulut C; Istanbul Health Directorate Public Health Laboratory-3, Istanbul, Turkey., Karaalp A; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Yananlı HR; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Güner AE; Istanbul Health Directorate, Istanbul, Turkey., Hatipoğlu M; Istanbul Health Directorate, Istanbul, Turkey., Karakurt S; Department of Pulmonary Medicine and Critical Care, Marmara University School of Medicine, Istanbul, Turkey., Korten V; Department of Infectious Disease and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey., Ratnaraj N; Department of Clinical and Experimental Epilepsy, University College London, Queen Square Institute of Neurology, London, UK., Patsalos P; Department of Clinical and Experimental Epilepsy, University College London, Queen Square Institute of Neurology, London, UK., Ay P; Department of Public Health, Marmara University School of Medicine, Istanbul, Turkey., Onat F; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey.; Department of Medical Pharmacology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Jul; Vol. 88 (7), pp. 3516-3522. Date of Electronic Publication: 2022 Feb 08. |
| DOI: | 10.1111/bcp.15227 |
| Abstrakt: | This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID-19 with a positive RT-PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in-hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID-19. The median favipiravir trough concentration (C (© 2022 British Pharmacological Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text